Ascendis Pharma approves $400M buyback; TransCon Semaglutide in-house
Ascendis Pharma A/S (NASDAQ: ASND) approved a $400M share repurchase program and moved once-monthly TransCon Semaglutide development back in-house after ending a 2024 collaboration.